Underuse of Evidence-Based Treatments in Psychiatry

Psychiatric Services

Volumn 54, Issue 11, 2003, Pages

  Fayek, Mohamed ^b   Flowers, Calvin ^b   Signorelli, Darln ^b   Simpson, George ^a  

^a LAC USC MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE UTILIZATION; HUMAN; MENTAL HEALTH CARE; SCHIZOPHRENIA; SHORT SURVEY; SUICIDAL BEHAVIOR; UNITED STATES;

EID: 10744221415     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.54.11.1453     Document Type: Short Survey

References (19)

1. Dwight-Johnson M, Lagomasino IT, Simpson GM, et al: Underuse of evidence-based pharmacotherapies for affective disorders. Psychiatric Services 54:1076-1078, 2003
2. The UK ECT Review Group: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361:799-808, 2003
3. Finlay-Jones R, Parker G: A consensus conference on psychotic depression. Australian and New Zealand Journal of Psychiatry 27: 581-589, 1993
4. Velligan DI, Lam F, Ereshefsky L, et al: Perspectives on medications adherence and atypical antipsychotic medications. Psychiatric Services 54:665-667, 2003
5. Johnson DAW: The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatrica Scandinavica 53:298-301, 1976
6. Hogarty GE, Schooler NR, Ulrich R, et al: Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analysis of a controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Archives of General Psychiatry 36:1283-1294, 1979
7. Adams CE, Fenton MK, Quraishi S, et al: Systematic: meta-review of depot antipsychotic drugs for people with schizophrenia. British Journal of Psychiatry 179:290-299, 2001
8. National Prescription Audit Database: Retail and Provider Perspective. Fairfield, Conn. IMS Health, 2002
9. Abulseoud O, Fayek M, Kingsbury SJ, et al: Patients' preference for conventional antipsychotic medications. Psychiatric Services 53:537-538, 547, 2002
10. Kane J, Hoidgfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic, a double-blind comparison with chlorpromazine. Archives of General psychiatry 45:789-796, 1988
11. Rosenheck R, Cramer J, Xu W, et al: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine 337:809-815, 1997
12. Essock SM, Hargreaves WA, Covell NH, et al: Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacology Bulletin 32:683-697, 1996
13. Marder SR: Evidence-based treatment for schizophrenia: a selected review. Contemporary Psychiatry, Dec 2002, pp 1-6
14. Geddes J, Freemantle N, Harrison P, et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321:1371-1376, 2000
15. Davis JM, Chen N, Click ID: A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry 60:553-564, 2003
16. Meltzer HY, Alphs L, Green Al, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial. Archives of General Psychiatry 60: 82-91, 2003
17. Citrome L, Volavka J, Czobor P, et al: Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatric Services 52:1510-1514, 2001
18. Simpson GM, Varga E: Clozapine: a new antipsychotic agent. Current Therapeutic Research, Clinical and Experimental 16: 679-686, 1974
19. Hayhurst KP, Brown P, Lewis SW, et al: Postcode prescribing for schizophrenia. British Journal of Psychiatry 182:281-283, 2003